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Background. Rotavirus vaccine  (Rotarix [RV1]) has reduced diarrhea-associated hospitalizations and deaths in Malawi. We 
examined the trends in circulating rotavirus genotypes in Malawi over a 22-year period to assess the impact of RV1 introduction on 
strain distribution.
Methods. Data on rotavirus-positive stool specimens among children aged <5  years hospitalized with diarrhea in Blantyre, 
Malawi before (July 1997–October 2012, n = 1765) and after (November 2012–October 2019, n = 934) RV1 introduction were ana-
lyzed. Rotavirus G and P genotypes were assigned using reverse-transcription polymerase chain reaction.
Results. A rich rotavirus strain diversity circulated throughout the 22-year period; Shannon (H′) and Simpson diversity (D′) 
indices did not differ between the pre- and postvaccine periods (H′ P < .149; D′ P < .287). Overall, G1 (n = 268/924 [28.7%]), G2 
(n = 308/924 [33.0%]), G3 (n = 72/924 [7.7%]), and G12 (n = 109/924 [11.8%]) were the most prevalent genotypes identified fol-
lowing RV1 introduction. The prevalence of G1P[8] and G2P[4] genotypes declined each successive year following RV1 introduc-
tion, and were not detected after 2018. Genotype G3 reemerged and became the predominant genotype from 2017 onward. No 
evidence of genotype selection was observed 7 years post–RV1 introduction.
Conclusions. Rotavirus strain diversity and genotype variation in Malawi are likely driven by natural mechanisms rather than 
vaccine pressure.
Keywords.  rotavirus; genotypes; gastroenteritis; Malawi; surveillance; Africa.
Rotavirus remains the leading cause of severe, dehydrating 
diarrhea among young children globally [1]. Vaccination is 
the primary public health approach to reduce the burden of 
rotavirus disease, and >100 countries have introduced rota-
virus vaccine into their immunization schedules (https://
vaccineresources.org/rotavirus.php). There has been a notable 
reduction in global rotavirus diarrhea-associated mortality 
following vaccine introduction, from more than half a mil-
lion deaths each year to an estimated 128 500 annual deaths 
among children <5 years of age. However, 258 million annual 
diarrhea episodes are still associated with rotavirus infection 
[2]. More than 90% of these cases occur in low- and middle-
income countries (LMICs), where rotavirus vaccine effective-
ness is lower (39%–66%) compared to high-income settings 
(>85%) [3, 4].
Since the introduction of the monovalent Rotarix G1P[8] 
rotavirus vaccine (RV1) into Malawi’s national immunization 
program on 29 October 2012 [4], there has been a 54.2% re-
duction in population rotavirus hospitalization incidence in 
children aged <5 years and a 33% reduction in infant mortality 
from all-cause diarrhea [5, 6]. Despite the positive impact of 
rotavirus vaccination in Malawi and other African countries, 
the burden of rotavirus disease remains high, and an estimated 
20–49.9 deaths in every 100 000 children aged <5 years are still 
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associated with rotavirus infection in the sub-Saharan region 
[2]. Given the greater rotavirus strain diversity in Africa [7, 8], 
there is a need to better understand the extent of heterotypic 
protection afforded by vaccination and the impact of vaccina-
tion on the diversity of circulating rotavirus strains.
Rotaviruses comprise their own genus within the Reoviridae 
family [9]. Their genome is composed of 11 segments of double-
stranded RNA (dsRNA) enclosed in triple capsulated protein 
layers. With the exception of segment 11 that encodes 2 proteins 
in some species, the remainder of the rotavirus genome segments 
encode a specific viral protein; hence, there are 6 structural 
(VP1–VP4, VP6, and VP7) and 6 nonstructural (NSP1–NSP6) 
proteins [9]. Rotaviruses are classified into 9 groups (A – I) 
based on the properties of their VP6 protein. Group A  rota-
viruses are associated with >90% of human infections and can 
be further differentiated using a dual classification system that 
assigns G and P genotypes based on nucleotide sequence simi-
larities of VP7 and VP4 encoding genome segments, respec-
tively [9]. So far, 36 G and 51 P rotavirus genotypes have been 
identified (http://rega.kuleuven.be/cev/viralmetagenomics/
virus-classification), of which G1P[8], G2P[4], G3P[8], G4P[8], 
G9P[8], and G12P[8] are the major global circulating strains 
in humans [10]. Unlike in high-income countries, a wide rota-
virus strain diversity is present in African countries where atyp-
ical rotaviruses including genotypes G1P[4], G1P[6], G8P[4], 
G8P[8], and G6P[6] are also frequently characterized [11–17]. 
Although a consistent change in the pattern of strains circu-
lating after the introduction of rotavirus vaccine has not yet 
been identified, a reduction in circulation of G1 rotaviruses 
and an increase in the detection of heterotypic strains [10], for 
instance G2P[4] rotaviruses in countries using RV1, has been 
reported in various settings [7, 18–20]. However, long-term 
studies are lacking from LMICs.
We have conducted rotavirus strain surveillance at the Queen 
Elizabeth Central Hospital (QECH) in Blantyre, Malawi, since 
1997; genotypes G1P[8], G2P[4], G3[P4], G3P[8], G4P[8], 
G8P[6], G8P[8], and G12P[8] were the most frequently de-
tected rotaviruses before and immediately following vaccine 
introduction [8, 11, 21–23]. To assess the impact of vaccine 
introduction on the diversity of circulating strains, we exam-
ined the trends in circulating rotavirus genotypes over a 22-year 
period (1997–2019), and compared the genotype diversities be-
tween rotaviruses that circulated before (1997–2012) and after 
(2012–2019) RV1 introduction.
MATERIALS AND METHODS
Rotavirus Surveillance Platform
We enrolled children <5  years old presenting to the QECH, 
Blantyre, with acute gastroenteritis (at least 3 looser-than-
normal stools in a 24-hour period). QECH is the main referral 
hospital in the southern region of Malawi that serves 23 gov-
ernment primary health centers within Blantyre city, which has 
a population of >1.25 million with a median age of 17.4 years 
according to the Malawi 2018 population census (http://www.
nsomalawi.mw).
We examined rotavirus genotypes identified from 2 periods 
of observation, reflecting pre- and postvaccine periods. 
Therefore, pre-RV1 genotypes were detected from July 1997 
to October 2012, whereas post-RV1 genotypes were detected 
from November 2012 to October 2019. Enrollment criteria 
were similar in both periods, incorporating both inpatients 
and outpatients, and included documentation of vaccine status 
from handheld health passports in the postvaccine period as 
described previously [5, 11, 12, 21, 23–25].
Rotavirus Detection and Genotyping
A minimum 20% stool suspension prepared in Rotaclone kit 
diluent buffer was used to screen for the presence of group 
A rotaviruses using a commercially available enzyme immu-
noassay (Rotaclone, Meridian Bioscience, Cincinnati, Ohio). 
Raw stool samples were stored at –80°C and were subse-
quently used to prepare 20% stool suspensions in phosphate-
buffered saline for molecular assays. Rotavirus dsRNA was 
extracted from freshly prepared rotavirus-positive stool sus-
pensions collected from 2011 to 2019 using the Viral RNA 
Mini-Kit (Qiagen, Hilden, Germany). Rotavirus dsRNA was 
reverse transcribed to complementary DNA (cDNA) using 
random primers (Invitrogen, Paisley, UK) and reverse tran-
scriptase enzyme (Superscript III MMLV-RT, Invitrogen) 
[26]. The cDNA was used to assign G genotype (G1, G2, G3, 
G4, G8, G9, G10, G11, G12) and P genotype (P[4], P[6], P[8], 
P[9], P[10], P[11], P[14]) to rotavirus-positive samples using 
a multiplex heminested reverse-transcription polymerase 
chain reaction (RT-PCR) assay as previously described [27]. 
For samples collected between 1997 and 2009, a guanidine 
and silica gel method was used to extract rotavirus dsRNA 
from stool, and the RT-PCR did not include G11, P[9], or 
P[14] genotype–specific primers [11]. Nucleotide sequencing 
was undertaken on at least 10% of the characterized geno-
types to confirm the RT-PCR–derived VP4 and VP7 geno-
types on randomly selected, representative strains using 
established methods [21, 28], followed by online genotyping 
using VIPR (https://www.viprbrc.org).
Rotavirus Genotype Diversity
Rotavirus genotype diversity during pre- and postvaccine 
periods was compared using the Simpson diversity index (D′) 
and Shannon diversity index (H′) [29]. In this context, Simpson 
diversity measures the probability that 2 rotavirus strains ran-
domly selected from a sample will belong to the same G and P 
genotype combination, whereas the Shannon index quantifies 
the uncertainty in predicting the rotavirus genotype of an in-
dividual sample randomly selected from the dataset. We em-
ployed the Simpson diversity index as a Simpson reciprocal 
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index (1 / D) [29]. Differentially abundant rotavirus genotypes 
were determined using IndVal, labdsv version 2.0_1, an indi-
cator species analysis package in R [30].
Statistical Analyses
Differences in genotype diversities between the pre- and 
postvaccine periods were calculated by Student t test or 
Wilcoxon signed-rank test. The χ 2 test or Fisher exact test were 
used to measure associations. Indicator species analysis was 
conducted to identify the genotypes that were significantly as-
sociated with a given group [31]. Statistical significance of ob-
served indicator species values was established by permutation 
tests, and P values were corrected for multiple comparisons with 
the Benjamini–Hochberg procedure at 10% false discovery rate.
To further investigate relative statistical changes in circu-
lating genotypes pre– and post–vaccine introduction in Malawi, 
we used multinomial logistic regression models, with genotype 
as the outcome and G1P[8] as the reference genotype. Model 
fitting included the following covariates: surveillance year 
(November–October), age in months, and sex. Multinomial 
odds ratios (MORs), 95% confidence intervals (CIs), and asso-
ciated P values were calculated from the Wald test. Due to lim-
ited study recruitment between November 2009 and October 
2011, these years were removed from the MOR analyses. All 
statistical analyses were performed in GraphPad Prism version 
8 and R package version 3.3.2 software [30].
Ethical Approval
Ethical approval was obtained from the National Health 
Sciences Research Committee, Lilongwe, Malawi (number 
867) and the Research Ethics Committee of the University of 
Liverpool, United Kingdom (000490).
RESULTS
Rotavirus Genotype Diversity (July 1997–October 2019)
 The percentage of stool samples in which rotaviruses 
were detected did not differ significantly before (33.4% 
[n = 1633/4896]) and after (29.6% [n = 934/3155]) RV1 in-
troduction. The relative abundance of rotavirus genotypes 
varied annually (Figure 1). The numbers of observed geno-
types (richness) per year was higher after RV1 introduction 
compared to the prevaccine period (P = .034); however, no 
significant differences were observed in the overall genotype 
diversity index between the pre– and post–RV1 introduc-
tion periods (Table  1). The increase in combined G and P 
genotype richness post–vaccine introduction was observed 
in children aged 12–23 months compared to the prevaccine 
period (P = .010; Table  1). When VP4 and VP7 genotypes 
were analyzed separately, significant differences were ob-
served in richness and diversity indices for P types; these dif-
ferences were greatest in children aged >12 months during 
the postvaccine period compared to the prevaccine period 
(Table 2 and Supplementary Table 1).
Trends in the Distribution of Rotavirus Genotypes (July 1997–October 2019)
With the exception of G1 strains (associated with either 
P[4], P[6], or P[8]), that consistently circulated from 1997 to 
2018, the distribution and relative proportion of other geno-
types fluctuated over time (Figure  1). For instance, G3P[4], 
G3P[6], G3P[8], G4P[4], and G4P[6] were detected between 
1997 and 1998, and then reemerged in 2017, whereas G4P[8] 
and G8P[6] prevailed from 1997 to 2007. Genotypes G8P[8], 
G9P[6], and G9P[8] circulated during 2001–2009 and then 
reemerged in 2018. G12 strains were detected for the first time 
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Figure 1. Trends of rotavirus strains from 1997 to 2019. A, Combined G and P genotypes of the genotyped samples. B, G genotypes only. C, P genotypes only. The size of 
the circle corresponds to the number of strains of that genotype detected in a given year.
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in 2005, of which G12P[6] was the first to appear, followed 
by G12P[8] in 2007 and then by G12P[4] in 2012. Although 
G12 strains associated with P[9], P[11], and P[14] were de-
tected sporadically between 2016 and 2019, G12 rotaviruses 
were highly prevalent between 2005 and 2015. Last, G2 rota-
viruses (associated with either P[4], P[6], or P[8]) were first 
detected in 2008, were the predominant rotaviruses identified 
during the early postvaccine period, and were highly preva-
lent until 2018. By the end of 2017, strains that prevailed in 
the 1990s, such as G3, G8, and G9s, had reemerged (Figure 1). 
Genotypes G8P[4] and G8P[6] were frequently detected before 
RV1 introduction, while the detection rate of G1P[4], G2P[4], 
G2P[6], G2P[8], and G12P[8] was significantly higher in the 
postvaccine period (Table 3).
After adjusting for surveillance year, age, and sex, the ad-
justed MOR (aMOR) of infection caused by G3P[8] (aMOR, 
1038 [95% CI, 1001–1078]; P < .001) and G3P[4] (aMOR, 4.01 
[95% CI, 4.01–4.02]; P < .001) was higher in the postvaccine 
period relative to wild-type G1P[8]. In contrast, cases due to 
G12P[6], G12P[8], G1P[6], G2P[4], and G2P[6] were lower in 
the postvaccine period relative to G1P[8], whereas cases due 
to mixed or other rarer genotypes were unchanged relative to 
G1P[8] (Figure 2).
Genotype Distribution Post–RV1 Introduction (November 2012– 
October 2019)
Among the 934 rotavirus-positive stool samples detected fol-
lowing RV1 introduction, 24 distinct genotypes were iden-
tified, of which G1P[8], G2P[4], G2P[6], G12P[6], G3P[4], 
G12P[8], G1P[6], and G3P[8] were the most common 
(Table 4). Overall, G1, G2, and G12 rotaviruses were the pre-
dominant strains during the first 5 years postvaccination, but 
their prevalence declined with each successive year. From 
2012 to 2017, the most common genotypes were G1P[8] 
and G2P[4], which alternated bi-ennially in predominance 
from 2012 to 2017 (Supplementary Figure 1). Genotype G3 
strains associated with either P[4], P[6], or P[8] were first 
detected in the postvaccination period in November 2017; of 
all strains detected in 2018 and 2019, 36.3% and 27.2% com-
prised G3P[4] and G3P[8], respectively. By the end of 2019, 
G3 strains had replaced G1 and G2 strains as the predomi-
nant genotypes (Figure 1 and Table 4).
The median age of children infected with any genotype, 
with the exception of genotype G9P[8], was higher after 
RV1 introduction (Supplementary Table 2). The geno-
type distribution among different age groups was generally 
similar; however, G12 strains were rarely detected among 
children aged >23  months, and genotype G3P[8] was de-
tected only in children aged 6–23 months. The proportion 
of mixed genotype infections increased in children aged 
<6  months in each consecutive year following RV1 intro-
duction (Supplementary Figure 2).Ta
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DISCUSSION
A rich diversity of rotavirus strains was detected among children 
hospitalized with diarrhea in Blantyre during >22 years of sur-
veillance. While we observed differences in the prevalence of 
individual rotavirus genotypes between pre– and post–RV1 
vaccine periods, overall combined G and P genotype diversity 
in the 2 periods was similar. Genotypes G1P[8] and G2P[4] 
predominated just prior to RV1 introduction and thereafter de-
clined in each successive year until 2018, after which they were 
not detected. In contrast, rotavirus strains that prevailed in the 
1990s reemerged post-2018, notably G3, which became the pre-
dominant genotype by the end of 2019.
Unlike in most high-income countries, a wide rotavirus 
strain diversity circulates simultaneously in many LMICs 
[10], where atypical rotavirus strains such as G1P[6], G8P[4], 
G8P[6], G8P[8], and G9P[6] are frequently detected [7, 10, 21, 
32]. In Malawi, up to 15 distinct rotavirus strains circulated 
within a single year (Figure 1). However, the impact of geno-
type diversity on vaccine performance remains unclear. Early 
studies suggested that strain diversity does not play a major role 
in determining vaccine efficacy [33], but the variability in ro-
tavirus vaccine effectiveness against different rotavirus strains 
demonstrated by postvaccine introduction studies suggests that 
there may be differences in protection against rotavirus disease 
caused by homotypic compared with heterotypic strains. Thus, 
RV1 pooled vaccine effectiveness against homotypic strains is 
higher compared to partially heterotypic or fully heterotypic 
strains both in high- and low-income countries [34]. This was 
also demonstrated in Malawi, where RV1 was more effective 
against genotype G1 (vaccine effectiveness, 70.7%) compared to 
G2 (45.9%) and G12 (51.0%) strains [5].
Despite genotype-specific differences in vaccine effective-
ness, it seems unlikely that the changes in rotavirus genotype 
distributions following vaccine introduction in Malawi could 
be attributed to selective vaccine pressure. For example, with 
each successive postvaccination year, G1 and G2 rotaviruses de-
clined in frequency and they were not detected after 2018; if the 
frequency of circulating strains was vaccine driven, a gradual 
and constant decline in the detection of G1 compared to G2 and 
G12 rotaviruses would have been expected. It is noteworthy, 
however, that changes in genotype distributions following vac-
cination have been observed in other settings, in particular a 
predominance of G2 strains following introduction of RV1 in 
South America, the Caribbean, Australia, and some European 
counties [18–20, 35], which could be a result of heterogeneity 
in the vaccine-induced responses [36]. A lower observed vac-
cine effectiveness or a higher force of rotavirus infection [5, 37] 
could explain why a shift in combined G and P genotype di-
versity has not yet been observed in Malawi post–RV1 intro-
duction, especially in children <12 months of age. Indeed, the 
cyclic pattern of circulating rotavirus strains in Malawi further 
suggests that the genotype changes were not driven by vaccine 
pressure but rather by a build-up and decline of homotypic im-
munity driven by natural rotavirus infection [38]. For example, 
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Figure 2. Multinomial odds ratios (MORs) for genotypes occurring before and after rotavirus vaccine introduction, November 1997–October 2019 (prevaccine period, 
n = 1422; postvaccine period, n = 896). Only full surveillance years were included in the multinomial regression analyses; therefore, rotavirus-positive genotyped samples from 
July to October 1997 (n = 84) and November 2009 to October 2011 (n = 7) were excluded from these analyses. Any single genotype that contributed ≤1.5% of samples in the 
whole study period was classified into a generic “other” category for “rarer” genotypes. P values for MORs: ***P < .001. G8P[6] was included in the model but not presented 
in Figure 2 because of extreme values related to there being no detections in the postvaccine era (adjusted MOR < 0.001).
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genotype G2 strains emerged in 2008, 4  years before vaccine 
introduction, and then could not be detected 10 years later in 
2018, similar to the 10-year cyclic circulation pattern observed 
for G2 rotaviruses in South Africa [39].
Regardless of the changes in genotype distributions, the 
overall prevalence of rotavirus has decreased substantially in 
all countries following rotavirus vaccine introduction. While 
in this study there was only a small decrease in the proportion 
of hospitalized diarrheal cases that tested positive for rotavirus 
following vaccine introduction among children aged <5 years, 
the greatest reduction in the prevalence of rotavirus in this 
population has been reported in those aged <12 months [40]. 
Furthermore, while we did not observe differences in the age 
distribution of children infected with different genotypes, the 
mean age of rotavirus cases increased during the vaccine period 
regardless of the infecting strain, providing additional evidence 
of vaccine impact [5]. Although there was no significant differ-
ence in the overall combined rotavirus G and P genotype di-
versity between the pre- and postvaccine periods, the diversity 
indices for P genotypes increased during the postvaccine period 
in children aged >12 months, similar to what was observed in 
children in England aged >6  months for combined G and P 
types [35]. Several possibilities may explain this observation. In 
Malawian children, a higher vaccine effectiveness (70.6%) is ob-
served during the first year of life compared to the second year 
of life (31.7%), and RV1 homotypic protection against G1P[8] 
genotypes is higher compared to non-G1P[8] heterotypic pro-
tection [5]. This, coupled with a high force of rotavirus infection 
in Malawi [37], likely exposes children to multiple genotypes as 
they grow older. Thus, with the lower vaccine-induced hetero-
typic protection, non-G1P[8] rotavirus genotypes would have 
increased fitness among vaccinated children, thereby permit-
ting them to persist in children aged >12  months until most 
have been exposed to multiple different strains. Further studies 
are warranted to investigate why, following vaccine introduc-
tion, diversity increased only in VP4 genotypes and not in VP7 
genotypes. Nevertheless, these findings support the role of VP4 
in mediating vaccine-induced protection and supports the use 
of recombinant VP5* (the stalk region of VP4) as useful targets 
for the development of improved third-generation rotavirus 
vaccines [41, 42].
Our study has some limitations. The diversity of genotypes 
that circulated prior to vaccine introduction could have been 
underestimated compared to the postvaccine years, as the 
RT-PCR assay used during the post–RV1 introduction period 
included additional genotype-specific primers. We did not de-
termine the frequency of the occurrence of nonspecific PCR 
product or PCR artifacts resulting from primer cross-binding 
or mismatches, which could have potentially resulted in over-
estimation of the proportion of mixed infections during the 
postvaccine era due to additional primers included in the 
genotyping cocktail [43]. It is likely, though, that the frequency 
of PCR artifacts was low, as all primers that were utilized are 
well validated and are used worldwide to genotype rotaviruses 
[27]. Nevertheless, our study provides a useful temporal ob-
servation of rotavirus strain variation and is one of the longest 
reported descriptions of rotavirus strains globally and, to our 
knowledge, the longest from a single site in Africa.
In conclusion, our comprehensive rotavirus strain surveil-
lance dataset spanning more than 2 decades demonstrates 
that genotype diversity did not significantly change following 
introduction of rotavirus vaccine. The overall variation in the 
prevalent rotavirus genotypes could not be attributed to vac-
cine introduction and most likely represents natural geno-
type oscillation. These data support continued use of rotavirus 
vaccination regardless of the circulating rotavirus genotypes. 
Nevertheless, continued strain surveillance is warranted to ac-
company ongoing vaccine impact evaluation and to monitor 
viral evolution.
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